2025
Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women
Nuckols V, Shoemaker L, Kuczmarski A, Haigh K, McGinty S, Del Vecchio A, Schwab A, Edwards D, Taylor H, Wenner M. Short-term estradiol administration does not restore endothelin‐B receptor‐mediated vasodilation in postmenopausal women. AJP Heart And Circulatory Physiology 2025, 328: h327-h332. PMID: 39773019, PMCID: PMC12175985, DOI: 10.1152/ajpheart.00815.2024.Peer-Reviewed Original ResearchConceptsPostmenopausal womenExogenous estradiol administrationEndothelin B receptorEstradiol administrationPremenopausal womenLactated RingeHealthy postmenopausal womenYoung womenLaser Doppler flowmetryEndothelin-BVasodilatory responseTransdermal patchDoppler flowmetryCutaneous microcirculationVasodilationEstradiolAdministrationWomenReceptorsRingerBlockadeFlowmetry
2024
Uterine fibroid–related infertility: mechanisms and management
Donnez J, Taylor H, Marcellin L, Dolmans M. Uterine fibroid–related infertility: mechanisms and management. Fertility And Sterility 2024, 122: 31-39. PMID: 38453041, DOI: 10.1016/j.fertnstert.2024.02.049.Peer-Reviewed Original ResearchUterine artery embolizationUterine fibroidsAssociation of fibroidsAdd-back therapyHeavy menstrual bleedingBaseline to weekOral GnRH antagonistPresence of fibroidsNon-surgical approachFocused ultrasoundFibroid volumeMyoma volumeArtery embolizationMenstrual bleedingCurrent management strategiesGnRH antagonistEchographic guidanceSurgical interventionFibroidsInfertilityMedical treatmentUterineWomenOptimal dosageSource of controversy
2023
Unexplained Female Infertility Associated with Genetic Disease Variants
Dougherty M, Poch A, Chorich L, Hawkins Z, Xu H, Roman R, Liu H, Brakta S, Taylor H, Knight J, Kim H, Diamond M, Layman L. Unexplained Female Infertility Associated with Genetic Disease Variants. New England Journal Of Medicine 2023, 388: 1055-1056. PMID: 36920765, PMCID: PMC10134047, DOI: 10.1056/nejmc2211539.Peer-Reviewed Original Research
2022
Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials
Donnez J, Taylor H, Stewart E, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland J, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials. Obstetrical & Gynecological Survey 2022, 77: 741-742. DOI: 10.1097/ogx.0000000000001113.Peer-Reviewed Original Research
2021
Fertility evaluation of infertile women: a committee opinion
Medicine P, Penzias A, Azziz R, Bendikson K, Cedars M, Falcone T, Hansen K, Hill M, Jindal S, Kalra S, Mersereau J, Racowsky C, Reindollar R, Shannon C, Steiner A, Stovall D, Tanrikut C, Taylor H, Yauger B. Fertility evaluation of infertile women: a committee opinion. Fertility And Sterility 2021, 116: 1255-1265. PMID: 34607703, DOI: 10.1016/j.fertnstert.2021.08.038.Peer-Reviewed Original ResearchParacetamol use during pregnancy — a call for precautionary action
Bauer AZ, Swan SH, Kriebel D, Liew Z, Taylor HS, Bornehag CG, Andrade AM, Olsen J, Jensen RH, Mitchell RT, Skakkebaek NE, Jégou B, Kristensen DM. Paracetamol use during pregnancy — a call for precautionary action. Nature Reviews Endocrinology 2021, 17: 757-766. PMID: 34556849, PMCID: PMC8580820, DOI: 10.1038/s41574-021-00553-7.Peer-Reviewed Original ResearchConceptsPregnant womenHealth professionalsBeginning of pregnancyLowest effective dosePublic health professionalsParacetamol useHigh feverModerate painSevere painPrenatal exposureUrogenital disordersConsensus statementImportant medicationsFetal developmentEffective doseEpidemiological researchPregnancyAPAPWomenMedicationsPainFeverLong-term basisFocused research effortExposureWillingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation
Pretzel S, Kuhn K, Pal L, Polotsky A, Taylor HS, Zhang H, Robins J, Young SL, Santoro N. Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation. Reproductive Sciences 2021, 29: 620-626. PMID: 34363198, PMCID: PMC8345905, DOI: 10.1007/s43032-021-00705-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChoice BehaviorCOVID-19Double-Blind MethodElectronic Health RecordsEndometriosisFemaleFertility Agents, FemaleFertilization in VitroGonadotropin-Releasing HormoneHealth Knowledge, Attitudes, PracticeHormone AntagonistsHumansInfertility, FemaleLive BirthPatient SelectionPregnancyPregnancy RateResearch SubjectsTreatment OutcomeUnited StatesYoung AdultConceptsGnRH antagonistClinical trialsEndometriosis diagnosisSuperior live birth ratesCOVID-19Relevant ICD-10 codesOral GnRH antagonistLive birth rateAge-eligible womenICD-10 codesElectronic medical recordsSurvey of womenIVF cyclesEligible womenWillingness of womenInfertility diagnosisMedical recordsFertility treatmentIVFWomenDiagnosisTrialsBirth rateTreatmentCOVID-19 pandemic
2020
Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis
Pokrzywinski RM, Soliman AM, Snabes MC, Chen J, Taylor HS, Coyne KS. Responsiveness and thresholds for clinically meaningful changes in worst pain numerical rating scale for dysmenorrhea and nonmenstrual pelvic pain in women with moderate to severe endometriosis. Fertility And Sterility 2020, 115: 423-430. PMID: 33066973, DOI: 10.1016/j.fertnstert.2020.07.013.Peer-Reviewed Original ResearchConceptsSevere endometriosis-associated painEndometriosis-associated painNumerical rating scaleNonmenstrual pelvic painPelvic painWorst painMonth 3Rating ScalePain numerical rating scaleMeaningful changePremenopausal womenSevere endometriosisGlobal ImpressionClinical trialsMAIN OUTCOMEPainDysmenorrheaPhase IIIWomenElagolixResponsivenessTrialsPlaceboEndometriosisPatientsUtility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons
Dolmans MM, Taylor HS, Rodriguez-Wallberg KA, Blumenfeld Z, Lambertini M, von Wolff M, Donnez J. Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons. Fertility And Sterility 2020, 114: 725-738. PMID: 33040981, DOI: 10.1016/j.fertnstert.2020.08.011.Peer-Reviewed Original ResearchEVALUATING THE RISK OF UNEXPLAINED INFERTILITY IN WOMEN WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS
Klionsky Y, Kotlyar A, Taylor H. EVALUATING THE RISK OF UNEXPLAINED INFERTILITY IN WOMEN WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS. Fertility And Sterility 2020, 114: e80-e81. DOI: 10.1016/j.fertnstert.2020.08.247.Peer-Reviewed Original ResearchReal-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
Surrey ES, Soliman AM, Johns B, Vora JB, Taylor HS, Agarwal SK. Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database. ClinicoEconomics And Outcomes Research 2020, 12: 473-479. PMID: 32922052, PMCID: PMC7456657, DOI: 10.2147/ceor.s264905.Peer-Reviewed Original ResearchAccurate Diagnosis of Endometriosis Using Serum MicroRNAs
Moustafa S, Burn M, Mamillapalli R, Nematian S, Flores V, Taylor H. Accurate Diagnosis of Endometriosis Using Serum MicroRNAs. Obstetrical & Gynecological Survey 2020, 75: 404-406. DOI: 10.1097/ogx.0000000000000816.Peer-Reviewed Original ResearchElagolix in the treatment of endometriosis: impact beyond pain symptoms
Archer DF, Soliman AM, Agarwal SK, Taylor HS. Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Therapeutic Advances In Reproductive Health 2020, 14: 2633494120964517. PMID: 33294846, PMCID: PMC7708701, DOI: 10.1177/2633494120964517.Peer-Reviewed Original ResearchPain symptomsSystemic manifestationsOral gonadotropin-releasing hormone receptor antagonistGonadotropin-releasing hormone receptor antagonistTreatment of endometriosisHormone receptor antagonistQuality of lifePelvic painSevere painCommon symptomsReceptor antagonistEndometriosisElagolixBeneficial effectsSymptomsPainManifestationsOutcomesPatientsWorkplace effectsAntagonistDiseaseWomen
2019
Uterine Cells Improved Ovarian Function in a Murine Model of Ovarian Insufficiency
Reig A, Mamillapalli R, Coolidge A, Johnson J, Taylor HS. Uterine Cells Improved Ovarian Function in a Murine Model of Ovarian Insufficiency. Reproductive Sciences 2019, 26: 1633-1639. PMID: 31530098, PMCID: PMC6949960, DOI: 10.1177/1933719119875818.Peer-Reviewed Original ResearchConceptsEndometrial mesenchymal stem cellsPrimary ovarian insufficiencyOvarian functionOvarian insufficiencyMurine modelSerum anti-Müllerian hormone concentrationsAnti-Müllerian hormone concentrationsStem cellsStem cell therapyOvarian dysfunctionUterine cell suspensionsHormone concentrationsMesenchymal stem cellsUterine cellsChemotherapyYoung womenCell therapyMiceOocyte poolIncreased numberWomenHigher body massSignificant increaseInsufficiencyPupsPrediction of pregnancy outcome in women with first trimester bleeding by the detection of alpha-fetoprotein (AFP) in vaginal blood
Mor A, Jubanyik K, Gardezi M, Nichols-Burns S, Zhang M, Esencan E, Simsek B, Seifer D, Taylor H. Prediction of pregnancy outcome in women with first trimester bleeding by the detection of alpha-fetoprotein (AFP) in vaginal blood. Fertility And Sterility 2019, 112: e312. DOI: 10.1016/j.fertnstert.2019.07.906.Peer-Reviewed Original Research
2018
Increased circulating miR-370-3p regulates steroidogenic factor 1 in endometriosis
Hu Z, Mamillapalli R, Taylor HS. Increased circulating miR-370-3p regulates steroidogenic factor 1 in endometriosis. AJP Endocrinology And Metabolism 2018, 316: e373-e382. PMID: 30576245, PMCID: PMC6459299, DOI: 10.1152/ajpendo.00244.2018.Peer-Reviewed Original ResearchConceptsEndometriotic cellsSteroidogenic factor 1Primary endometriotic cellsReproductive-aged womenAltered expressionSera of patientsPathogenesis of endometriosisCell proliferationFactor 1SF-1Novel therapeutic strategiesSteroidogenic acute regulatory proteinGynecologic diseaseEndometrial tissueEndometriotic lesionsAcute regulatory proteinSF-1 mRNA levelsEndometriosisTherapeutic strategiesEstrogen biosynthesisMRNA levelsRespective controlsWomenEssential transcriptional regulatorSerum86 Elagolix Reduced Dyspareunia and Improved Health-Related Quality of Life in Premenopausal Women with Endometriosis-Associated Pain
Leyland N, Taylor H, Archer D, Peloso P, Schwefel B, Soliman A, Martinez M, Abrao M. 86 Elagolix Reduced Dyspareunia and Improved Health-Related Quality of Life in Premenopausal Women with Endometriosis-Associated Pain. Journal Of Minimally Invasive Gynecology 2018, 25: s55-s56. DOI: 10.1016/j.jmig.2018.09.093.Peer-Reviewed Original Research741 Patient Experience and Clinical Presentation of US Women with Uterine Fibroids: Results from the First 200 Women Enrolled in a National Real-World Study
Taylor H, Liu J, Al-Hendy A, Jackson-Bey T, Bradley L, Moon K, Kerolous M. 741 Patient Experience and Clinical Presentation of US Women with Uterine Fibroids: Results from the First 200 Women Enrolled in a National Real-World Study. Journal Of Minimally Invasive Gynecology 2018, 25: s281-s282. DOI: 10.1016/j.jmig.2018.09.754.Peer-Reviewed Original ResearchDevelopment of the Painful Periods Screening Tool for endometriosis
DiBenedetti DB, Soliman AM, Ervin C, Evans E, Coddington CC, Agarwal SK, Surrey ES, Taylor HS. Development of the Painful Periods Screening Tool for endometriosis. Postgraduate Medicine 2018, 130: 694-702. PMID: 30334456, DOI: 10.1080/00325481.2018.1526623.Peer-Reviewed Original ResearchConceptsEndometriosis symptomsHealthy controlsScreening toolEndometriosis-related symptomsTreatment of endometriosisCross-sectional qualitative studyDiagnostic delayEarly diagnosisEndometriosisUnmet needCore symptomsSymptomsClinical expertsDraft itemsWomenPatientsDepth individual interviewsPhysiciansQualitative studyIndividual interviewsRounds of interviewsDiagnosisElagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain
Leyland N, Taylor H, Archer D, Peloso P, Schwefel B, Soliman A, Martinez M, Abrao M. Elagolix reduced dyspareunia and improved health-related quality of life in premenopausal women with endometriosis-associated pain. Fertility And Sterility 2018, 110: e82-e83. DOI: 10.1016/j.fertnstert.2018.07.249.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply